Literature DB >> 16905695

A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results.

P Sharma1, S Wani, A P Weston, A Bansal, M Hall, S Mathur, A Prasad, R E Sampliner.   

Abstract

BACKGROUND: Many modalities have been used to ablate Barrett's oesophagus (BO). However, long term results and comparative effectiveness are unknown. AIMS: Our aim was to compare the long term efficacy of achieving complete reversal (endoscopic and histological) between multipolar electrocoagulation (MPEC) and argon plasma coagulation (APC) in BO patients and assess factors influencing successful ablation.
METHODS: Patients with BO, 2-6 cm long, underwent 24 hour pH testing on proton pump inhibitor (PPI) therapy. Patients were then randomised by BO length to undergo ablation with MPEC or APC every 4-8 weeks until endoscopic reversal or maximal of six treatment sessions.
RESULTS: Thirty five BO patients have been followed for at least two years following endoscopic ablation, 16 treated with MPEC and 19 with APC. There was complete reversal of BO in 24 patients (69%); 75% with MPEC and 63% with APC (p = 0.49). There was no difference in the number of sessions required in the two groups. There was no difference in age, pH results, BO length, PPI dose, or hiatal hernia size between patients with and without complete reversal. One patient developed an oesophageal stricture but there were no major complications such as bleeding or perforation.
CONCLUSIONS: In BO patients treated with MPEC or APC in combination with acid suppression, at long term follow up, complete reversal of BO can be maintained in approximately 70% of patients, irrespective of the technique. There are no predictors associated with achieving complete reversal of BO. Continued surveillance is still indicated in the post ablative setting. As yet, these techniques are not ready for clinical application (other than for high grade dysplasia or early oesophageal adenocarcinoma) and cannot be offered outside the research arena.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905695      PMCID: PMC1860010          DOI: 10.1136/gut.2005.086777

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  39 in total

1.  Adenocarcinoma arising in columnar lined oesophagus following treatment with argon plasma coagulation.

Authors:  A Shand; H Dallal; K Palmer; S Ghosh; M MacIntyre
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

2.  Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus.

Authors:  Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

3.  Adenocarcinoma in Barrett's esophagus: a new epidemic?

Authors:  R C Haggitt
Journal:  Hum Pathol       Date:  1992-05       Impact factor: 3.466

4.  Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study.

Authors:  R E Sampliner; D Faigel; M B Fennerty; D Lieberman; A Ippoliti; K Lewin; W M Weinstein
Journal:  Gastrointest Endosc       Date:  2001-05       Impact factor: 9.427

5.  Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus.

Authors:  J L Van Laethem; M O Peny; I Salmon; M Cremer; J Devière
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

6.  Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium.

Authors:  K K Basu; B Pick; R Bale; K P West; J S de Caestecker
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

Review 7.  The changing epidemiology of esophageal cancer.

Authors:  W J Blot; J K McLaughlin
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

8.  High power setting argon plasma coagulation for the eradication of Barrett's esophagus.

Authors:  J C Pereira-Lima; J V Busnello; C Saul; E B Toneloto; C V Lopes; C B Rynkowski; C Blaya
Journal:  Am J Gastroenterol       Date:  2000-07       Impact factor: 10.864

9.  Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus.

Authors:  Richard E Sampliner; Lisa Camargo; Ronnie Fass
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

10.  Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation.

Authors:  Nicole Carlson; Juan Lechago; Joel Richter; Richard E Sampliner; Leif Peterson; Regina M Santella; John R Goldblum; Gary W Falk; Atilla Ertan; Mamoun Younes
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

View more
  28 in total

1.  Sixteen-year follow-up of Barrett's esophagus, endoscopically treated with argon plasma coagulation.

Authors:  Mariana Milashka; Annabelle Calomme; Jean Luc Van Laethem; Daniel Blero; Pierre Eisendrath; Olivier Le Moine; Jacques Devière
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

Review 2.  Guidelines for surgical treatment of gastroesophageal reflux disease.

Authors:  Dimitrios Stefanidis; William W Hope; Geoffrey P Kohn; Patrick R Reardon; William S Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2010-08-20       Impact factor: 4.584

3.  Ablating Barrett's metaplastic epithelium: are the techniques ready for clinical use?

Authors:  J J G H M Bergman; P Fockens
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

Review 4.  A systematic review and meta-analysis of the treatment for Barrett's esophagus.

Authors:  You-Ming Li; Lan Li; Chao-Hui Yu; You-Shi Liu; Cheng-Fu Xu
Journal:  Dig Dis Sci       Date:  2008-04-22       Impact factor: 3.199

Review 5.  Ablative therapies for Barrett's esophagus.

Authors:  Katherine S Garman; Nicholas J Shaheen
Journal:  Curr Gastroenterol Rep       Date:  2011-06

Review 6.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

7.  How I Treat Patients With Barrett Esophagus When Endoscopic Ablation Fails.

Authors:  Kenneth K Wang
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-02

Review 8.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

9.  Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus.

Authors:  Bruce D Greenwald; John A Dumot; J David Horwhat; Charles J Lightdale; Julian A Abrams
Journal:  Dis Esophagus       Date:  2009-06-09       Impact factor: 3.429

10.  Barrett's esophagus: where do we stand?

Authors:  Majid A Al Madi
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.